NexImmune, Inc. NEXI
- Market cap
- $1.6M
- P/E
- 0.0×
Follow NEXI
Target Price Range
Analyst price targets
Free account| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | 100.25 | 4.87 | 1.25 |
Analyst estimates 2024–2026 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | 700.00 | 122.75 | 20.35 |
High Price
|
|||
| — | — | — | — | — | — | 44 | 74 | 50 | 6 |
Employees
|
|||
| — | — | — | — | — | — | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Gross Margin
|
|||
| — | — | — | — | (13) | (21) | (30) | (51) | (63) | (32) |
EBT
|
|||
| — | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | 0 | (13) | (21) | (30) | (51) | (63) | (32) |
Net Income
|
|||
| — | — | — | — | 0 | 0 | 1 | 1 | 1 | 1 |
Depreciation
|
|||
| — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | (16.55) | (414.09) | (660.50) | (63.50) | (65.00) | (30.82) |
Earnings/Sh
|
|||
| — | — | — | — | (12.34) | (391.44) | (525.99) | (56.71) | (53.19) | (29.95) |
Cash Flow/Sh
|
|||
| — | — | — | — | 0.00 | (25.12) | (17.23) | (2.91) | (1.22) | (0.04) |
Capex/Sh
|
|||
| — | — | — | — | (12.34) | (416.56) | (543.22) | (59.62) | (54.41) | (29.99) |
Free CF/Sh
|
|||
| — | — | — | — | (26.90) | (867.13) | (1,381.97) | 103.74 | 33.56 | 3.34 |
Book Value/Sh
|
|||
| — | — | — | — | 1 | 0 | 0 | 1 | 1 | 1 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | (11) | (19) | (26) | (46) | (51) | (31) |
Op' Cash Flow
|
|||
| — | — | — | — | (1) | (1) | (1) | (2) | (1) | 0 |
Capex
|
|||
| — | — | — | — | (11) | (21) | (27) | (48) | (52) | (31) |
FCF
|
|||
| — | — | — | — | 9 | 8 | (19) | 79 | 27 | 0 |
Working Cap'
|
|||
| — | — | — | — | 35 | 54 | 19 | — | 1 | — |
Total Debt
|
|||
| — | — | — | — | 23 | (10) | 14 | (82) | (34) | (3) |
Net Debt
|
|||
| — | — | — | — | (24) | (43) | (69) | 84 | 32 | 4 |
Sh' Equity
|
|||
| — | — | — | — | (210.81%) | (166.59%) | (264.97%) | (100.22%) | (93.23%) | (125.24%) |
ROA
|
|||
| — | — | — | — | 0.00% | 0.00% | 0.00% | (1,775.29%) | 0.00% | (7,175.66%) |
ROIC
|
|||
| — | — | — | — | 44.33% | 69.02% | 58.99% | (712.92%) | (107.71%) | (180.64%) |
ROE
|
|||
NexImmune, Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ITRMF Iterum Therapeutics PLC | $1.6M | 0.0× | Compare |
| FNCHQ Finch Therapeutics Group, Inc. | $1.6M | 0.0× | Compare |
| CARM Carisma Therapeutics Inc. | $1.5M | 0.0× | Compare |
| SLXN Silexion Therapeutics Corp | $1.4M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ABPO Abpro Holdings Inc. | $1.4M | 0.2× | Compare |
| TRVN Trevena, Inc. | $1.8M | 0.0× | Compare |
| CRIS Curis, Inc. | $1.8M | 0.0× | Compare |
| BBLG Bone Biologics Corp. | $1.4M | 0.0× | Compare |
NexImmune, Inc. (NEXI) Latest News
6 Feb
NexImmune closed a $3.67 million registered direct offering priced at-the-market under Nasdaq rules. The offering will provide additional financing for potential business development and collaboration opportunities.
2 Feb
NexImmune announces $3.67 million registered direct offering priced at-the-market under Nasdaq rules. The offering and potential business development opportunities are expected to significantly impact NexImmune's future trajectory and market performance.
1 Dec
NexImmune, Inc. (NEXI) shares soar over 77% in pre-market trading. Other top gainers and losers listed. Significant impact likely on NexImmune's future performance due to the substantial increase in share price.
24 Oct
NexImmune, Yale, and JDRF extend research partnership to explore nanoparticles and anti-CD3 mAb for type 1 diabetes. The partnership extension and research focus on potential treatment for type 1 diabetes could have a significant impact on NexImmune's future product development and market performance.
19 Oct
NexImmune to present abstracts at SITC 38th Annual Meeting showcasing advancements in AIM injectable program and ACT combination in oncology. The presentations at the SITC meeting demonstrate significant advancements in NexImmune's platform and potential therapeutic applications.
18 Oct
NexImmune, Inc. announced a 1-for-25 reverse stock split to increase per share trading price and regain compliance with Nasdaq listing requirements. The reverse stock split will impact the company's financial performance and market positioning, but the overall effect is expected to be somewhat limited.
31 Aug
NexImmune announces workforce reduction to focus on AIMTM nanoparticle platform development. The workforce reduction to enable platform development may have a moderately noticeable influence on NexImmune's competitive positioning and product innovation.
10 Aug
NexImmune reports Q2 2023 financial results and business updates. The financial results and business updates may moderately influence NexImmune's performance and competitive positioning.
5 Jun
NexImmune presents positive data from NEXI-001 Phase 1 trial for relapsed/refractory post allo-HSCT AML at ASCO 2023 Annual Meeting. Positive data from Phase 1 trial with favorable safety profile and clinical activity could significantly impact NexImmune's future and market performance.
22 May
NexImmune to present poster at FOCIS Annual Meeting on AIM nanoparticle approach for EBV-specific T cell defects in MS patients. The potential therapeutic role for AIM products in addressing T cell defects and killing EBV+ cells in MS could significantly impact NexImmune's future and market performance.
15 May
NexImmune reports first quarter 2023 financial results and provides business updates. The article highlights significant progress in clinical and preclinical research, financial performance, and strategic collaborations that could have a major impact on NexImmune's future.